0
0
The European Medicines Agency (EMA) has started the review process for a new CoV drug. Swedish-British manufacturer AstraZeneca has developed Evusheld, a combination drug designed to prevent Covid-19 disease in adults, the EMA said today in Amsterdam. Initial test results indicated the drug was effective in protecting against the disease.
Only Remdesivier approved so far
Experts are now continuously evaluating data from tests and weighing the benefits and drawbacks of the drug. It is not known when a final result will be available. According to the authorities, the manufacturer has not yet submitted an application for approval for the European market. The drug consists of the active ingredients tixagevimab and cilgavimab.
So far, only the drug Remdesivir has been approved in the EU as a specific Covid-19 drug. Approval procedures are currently underway for five compounds. A total of three agents are still under review by the EMA.
- source: ORF.at/agencies/picture:
This post has already been read 743 times!
